Literature DB >> 16557268

p53 and disease: when the guardian angel fails.

J A Royds1, B Iacopetta.   

Abstract

The p53 tumor suppressor gene (TP53) is mutated more often in human cancers than any other gene yet reported. Of importance, it is mutated frequently in the common human malignancies of the breast and colorectum and also, but less frequently, in other significant human cancers such as glioblastomas. There is also one inherited cancer predisposing syndrome called Li-Fraumeni that is caused by TP53 mutations. In this review, we discuss the significance of p53 mutations in some of the above tumors with a view to outlining how p53 contributes to malignant progression. We also discuss the usefulness of TP53 status as a prognostic marker and its role as a predictor of response to therapy. Finally, we outline some evidence that abnormalities in p53 function contribute to the etiology of other non-neoplastic diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16557268     DOI: 10.1038/sj.cdd.4401913

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  55 in total

1.  Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53.

Authors:  Lorna Jane Warnock; Sally Anne Raines; Jo Milner
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

2.  p53 modulates acquired resistance to EGFR inhibitors and radiation.

Authors:  Shyhmin Huang; Sergio Benavente; Eric A Armstrong; Chunrong Li; Deric L Wheeler; Paul M Harari
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

3.  Inappropriate activation of cyclin-dependent kinases by the phosphatase Cdc25b results in premature mitotic entry and triggers a p53-dependent checkpoint.

Authors:  Shohreh Varmeh; James J Manfredi
Journal:  J Biol Chem       Date:  2009-01-09       Impact factor: 5.157

4.  Effective Targeting Survivin, Caspase-3 and MicroRNA-16-1 Expression by Methyl-3-pentyl-6-methoxyprodigiosene Triggers Apoptosis in Colorectal Cancer Stem-Like Cells.

Authors:  Sohrab Sam; Mohammad Reza Sam; Mohammad Esmaeillou; Reza Safaralizadeh
Journal:  Pathol Oncol Res       Date:  2016-04-07       Impact factor: 3.201

5.  Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Authors:  Min H Kang; C Patrick Reynolds; E Anders Kolb; Richard Gorlick; Hernan Carol; Richard Lock; Stephen T Keir; John M Maris; Jianwrong Wu; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2016-05-30       Impact factor: 3.167

6.  The expression of PCNA, c-erbB-2, p53, ER and PR as well as atypical hyperplasia in tissues nearby the breast cancer.

Authors:  Zongliang Jia; Wei Zhao; Lin Fan; Wei Sheng
Journal:  J Mol Histol       Date:  2011-11-05       Impact factor: 2.611

Review 7.  Versatile functions of p53 protein in multicellular organisms.

Authors:  P M Chumakov
Journal:  Biochemistry (Mosc)       Date:  2007-12       Impact factor: 2.487

Review 8.  Connecting molecular pathways to hereditary cancer risk syndromes.

Authors:  Joseph R Testa; David Malkin; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

9.  Transitions at CpG dinucleotides, geographic clustering of TP53 mutations and food availability patterns in colorectal cancer.

Authors:  Fabio Verginelli; Faraz Bishehsari; Francesco Napolitano; Mahboobeh Mahdavinia; Alessandro Cama; Reza Malekzadeh; Gennaro Miele; Giancarlo Raiconi; Roberto Tagliaferri; Renato Mariani-Costantini
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

10.  Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

Authors:  W Chua; D Goldstein; C K Lee; H Dhillon; M Michael; P Mitchell; S J Clarke; B Iacopetta
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.